Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2506, a proposed biosimilar of Simponi® (golimumab), to EU-sourced Simponi® in normal...
D&D Pharmatech, based in Gyenggi-Do, Korea and Germantown, Maryland, closed on a Series B financing round worth $137.1 million. The financing was led by U.S.-based Octave Life Sciences and Korean venture firm Smilegate Investment. Investors included InterVest,...
Emalex Biosciences, Inc., a biopharmaceutical company developing innovative therapies for patients with neurological and psychiatric conditions, announced today that the first patient was recently enrolled in the company’s international Phase 2b study to evaluate the...
Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”),...
Clinical development plan and Accelerated Approval regulatory path confirmed Phase 3 trial to initiate in the first quarter of 2020 and intended to support both major bleeding and surgery indications Conference call and webcast today at 8:30 a.m. EDT MALVERN, Pa. and...
Henry Ford Cancer Institute is first-in-the-world to enroll a patient in the GBM AGILE Trial (Adaptive Global Innovative Learning Environment) – a novel trial design and architecture made possible by an international collaboration of experts in the care of patients...
Email
Text